

The Mary

Express Mail No. <u>EV 475 142 215 US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Taylor et al.

Confirmation No.: 4486

Serial No.: 10/016,763

Art Unit: 1644

Filed: October 26, 2001

Examiner: Francois P. VanderVegt

For:

ANTIGEN-BASED HETEROPOLYMERS AND

Attorney Docket No: 9426-059-999

METHOD FOR TREATING AUTOIMMUNE

DISEASES USING THE SAME

AMENDMENT FEE TRANSMITTAL SHEET

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$ 0.00.

Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: April 7, 2006 Warst B. Brivanlou (Reg. No.)

By: Allian L. Younn

(Reg No.)

(Keg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017-6702

(212) 901-9028

Express Mail No. EV 475 142 215 US

in the unit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TAPPRICATION of: Taylor et al.

Confirmation No.: 4486

Serial No.: 10/016,763

Art Unit: 1644

Filed: October 26, 2001

Examiner: Francois P. VanderVegt

For:

ANTIGEN-BASED HETEROPOLYMERS AND

Attorney Docket No: 9426-059-999

METHODS FOR TREATING AUTOIMMUNE

DISEASES USING THE SAME

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the outstanding Office Action mailed November 7, 2005, in which the Examiner issued a restriction requirement, please consider the remarks made below in connection with the above-identified patent application. Submitted concurrently herewith are (i) a Petition for an Extension of Time for Response for four (4) months from December 7, 2005 to and including April 7, 2006, accompanied by the appropriate fee; (ii) an Amendment Fee Transmittal Sheet; and (iii) an Assertion Of Small Entity Status Under 37 C.F.R. § 1.27(c).

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.